Quick Answer
IMMUCELL CORP /DE/ reported Total Revenue of $27.64 million for fiscal year 2025.
IMMUCELL CORP /DE/ — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $27.64M +4.3% |
$26.49M +51.6% |
$17.47M | — | — | — |
| Revenue (ASC 606) | $27.64M +4.3% |
$26.49M | — | — | — | — |
| Net Income | -$1.04M +51.8% |
-$2.16M +62.7% |
-$5.77M -131.6% |
-$2.49M -3085.3% |
-$78.3K +92.3% |
-$1.02M +21.1% |
| Diluted EPS | -$0.12 +53.8% |
-$0.26 +65.3% |
-$0.75 -134.4% |
-$0.32 -3100.0% |
-$0.01 +92.9% |
-$0.14 +26.3% |
| Total Assets | $42.53M -5.7% |
$45.10M +3.0% |
$43.81M -2.3% |
$44.86M +0.9% |
$44.47M +10.2% |
$40.35M +4.3% |
| Cash and Equivalents | $3.81M +1.3% |
$3.76M +284.0% |
$978.7K -83.1% |
$5.79M -43.1% |
$10.19M +46.6% |
$6.95M +10.4% |
| Long-Term Debt | $7.49M -17.2% |
$9.04M | — | — | — | — |
| Stockholders Equity | $27.06M -1.7% |
$27.52M +10.1% |
$24.99M -17.7% |
$30.38M -6.7% |
$32.58M +15.3% |
$28.27M -2.5% |
| R&D Expense | $3.04M -22.0% |
$3.90M -11.3% |
$4.39M -2.2% |
$4.49M +7.8% |
$4.17M -4.3% |
$4.35M +18.1% |
| Operating Income | $1.65M +200.6% |
-$1.64M +71.5% |
-$5.75M -150.0% |
-$2.30M -993.2% |
$257.4K +118.6% |
-$1.38M -44.7% |
| Gross Profit | $11.45M +44.1% |
$7.94M +105.2% |
$3.87M -49.4% |
$7.65M -11.6% |
$8.66M +26.1% |
$6.86M +1.8% |
| Shares Outstanding | 9.05M +0.7% |
8.98M +15.8% |
7.75M +0.1% |
7.75M +0.1% |
7.74M +7.2% |
7.22M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.51M | -8.4% | -14.6% |
| Revenue (ASC 606) | September 30, 2025 | $5.51M | -8.4% | -8.4% |
| Net Income | September 30, 2025 | -$139.7K | +80.1% | -127.8% |
| Diluted EPS | September 30, 2025 | -$0.02 | +77.8% | -133.3% |
| Total Assets | September 30, 2025 | $45.73M | +2.9% | -2.1% |
| Cash and Equivalents | September 30, 2025 | $3.89M | — | +3.4% |
| Long-Term Debt | September 30, 2025 | $7.90M | — | -4.4% |
| Stockholders Equity | September 30, 2025 | $29.80M | +12.8% | -0.2% |
| R&D Expense | September 30, 2025 | $694.3K | -11.7% | -16.5% |
| Operating Income | September 30, 2025 | $20.1K | +103.5% | -96.5% |
| Gross Profit | September 30, 2025 | $2.36M | +49.2% | -16.1% |
| Shares Outstanding | September 30, 2025 | 9.05M | +2.4% | +0.0% |
- IMMUCELL CORP /DE/ reported Total Revenue of $27.64 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +4.3% in Total Revenue compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Revenue (ASC 606) of $27.64 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Net Income of -$1.04 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +51.8% in Net Income compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +53.8% in Diluted EPS compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Total Assets of $42.53 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed a decrease of -5.7% in Total Assets compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Cash and Equivalents of $3.81 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +1.3% in Cash and Equivalents compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Long-Term Debt of $7.49 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed a decrease of -17.2% in Long-Term Debt compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Stockholders Equity of $27.06 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed a decrease of -1.7% in Stockholders Equity compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported R&D Expense of $3.04 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed a decrease of -22.0% in R&D Expense compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Operating Income of $1.65 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +200.6% in Operating Income compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Gross Profit of $11.45 million for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +44.1% in Gross Profit compared to the prior fiscal year.
- IMMUCELL CORP /DE/ reported Shares Outstanding of 9.05 million shares for fiscal year 2025.
- IMMUCELL CORP /DE/ showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: